Analystreport

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its "buy" rating re-affirmed by analysts at Piper Sandler. They now have a $26.50 price target on the stock.

Milestone Pharmaceuticals Inc. - Common Shares  (MIST) 
Last milestone pharmaceuticals inc. - common shares earnings: 3/6 07:00 am Check Earnings Report